To Study the Role of Personalized Risk Factors for Poor Response to Angiostatic Therapy Based on Regression Models of the Disease
https://doi.org/10.18008/1816-5095-2025-1-136-142
Abstract
Purpose: to study the role of personalized risk factors for poor response to angiostatic therapy based on a regression model of the disease.
Patients and methods. The study had a retrospective cohort design, including 84 patients (92 eyes) with a newly diagnosed MNV and evidence of disease activity. In 18 (19.5 %) people, the process was bilateral. Personalized retinal morphometrics and intraocular pressure (IOP) in eyes with MNV treated with fixed intravitreal injections (IVI) of Eylea in correlation with treatment response were studied. Treatment response was ranked into five types. Treatment results were assessed clinically and morphometrically by optical coherence tomography (OCT). Based on the results of correlations, logistic regression models of the disease were built. They studied the role of various factors in the treatment of the disease and the strength of their association with an adverse outcome.
Results. 2 models of the disease have been developed and presented in the form of logistic regression equations with formulas for calculating the prognosis of the effectiveness of treatment with angiostatics. The strength of the risk factors association for an adverse response was analyzed, such as the height of pigment epithelial detachment, the presence of intraretinal edema, personalized intraocular pressure indicators of the affected eye, the patient’s disease belonging to the hereditary form of AMD, the presence of bad habits (smoking). It is shown that an increase in the height of pigment epithelial detachment (marker PED_H = 170 microns) by 1 micron, with other unchanged predictors, increases the ratio of the chance of a negative outcome to a positive one by 1%. At this marker value, the sensitivity of the poor response to angiostatic treatment was 0.493 and the specificity was 0.737. When intraretinal edema occurs, the ratio of the chance of a negative outcome to a positive outcome increases by 68 %. In conditions of increased intraocular pressure, the risk of a poor response increases by 4 times. The prognosis for a smoker is 30% worse compared to a nonsmoking patient. Hereditary AMD increases the risk of developing a poor response to treatment by 25 %. Conclusion. A logistic regression model of the disease is presented, which correctly predicts 94 % of non-response, which makes the prognosis reliable, reliable and accurate. Modifiable (smoking, PED_H > 170 microns, presence of IRF, increased IOP) and non-modifiable (hereditary norm of the disease) risk factors that are important in practical ophthalmology and increase the likelihood of developing an unfavorable outcome of angiostatic treatment were analyzed.
About the Authors
V. G. LikhvantsevaRussian Federation
Likhvantseva Vera G., МD, consultant of the Сlinical and diagnostic center of ophthalmology, Professor of the Ophthalmology Department
15 Gamalei str., Moscow, 123098
Volokolamskoe highway, 91, Moscow, 125310
S. G. Kapkova
Russian Federation
Kapkova Svetlana G., Head of the Ophthalmology Department, PhD, Assistant Professor of the Ophthalmology Department
15 Gamalei str., Moscow, 123098
Volokolamskoe highway, 91, Moscow, 125310
15 Gamalei Str., Moscow, 123098
E. B. Tretyak
Russian Federation
Tretyak Evgeniya B., PhD, ophthalmologist
15 Gamalei str., Moscow, 123098
V. I. Naumova
Russian Federation
Naumova Victoria I., ophthalmologist, Department of Ophthalmology
15 Gamalei str., Moscow, 123098
H. M. Plieva
Russian Federation
Plieva Khava M., assistant at the Department of Eye Diseases, Ophthalmologist
Volokolamskoe highway, 91, Moscow, 125310
15 Gamalei str., Moscow, 123098
T. E. Borisenko
Russian Federation
Borisenko Tatyana Е., statistician
Rossolimo str., 11A, B, Moscow 119021
References
1. Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, Gomes AV, Warburton J, Weichselberger A, Holz FG; HAWK and HARRIER Study Investigators. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2020 Jan;127(1):72–84. doi: 10.1016/j.ophtha.2019.04.017.
2. Eyetech Study Group: Preclinical and phase IA clinical evalution of anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina. 2002;22(2):143–152. doi: 10.1097/00006982-200204000-00002.
3. Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K. SEVEN-UP Study Group Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120(11):2292–2299. doi: 10.1016/j.ophtha.2013.03.046.
4. Rosenfeld PJ, Brown DM, Heier J.S. MARINA Study Group Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–1431. doi: 10.1056/nejmoa054481.
5. Samanta A, Aziz AA. Emerging Therapies in Neovascular Age-Related Macular Degeneration in 2020. Asia Pac. J. Ophthalmol. (Phila.). 2020;9:250–259. doi: 10.1097/APO.0000000000000291.
6. Schmidt-Erfurth U, Eldem B, Guymer R, Korobelnik JF, Schlingemann RO, Axer-Siegel R, Wiedemann P, Simader C, Gekkieva M, Weichselberger A; EXCITE Study Group. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology. 2011 May;118(5):831–839. doi: 10.1016/j.ophtha.2010.09.004.
7. Neroev VV, Short SA, Bobykin EV., Zaitseva O.V. Information leaflet for patients receiving treatment with intravitreal drug administration. Recommendations of the Expert Council on Diseases of the Retina and Optic Nerve of the All-Russian Public Organization “Association of Ophthalmologists”. Russian Ophthalmological Journal. 2021;14(S2):7–19 (In Russ). doi: 10.21516/2072-0076-2021-14-2-supplement-7-19.
8. Fayzrakhmanov RR. Prescribing regimens of anti-VEGF drugs in the therapy of neovascular age-related macular degeneration. Vestnik oftal’mologii. 2018;6:105–113 (In Russ). doi: 10.21516/2072-0076-2019-12-2-97-105.
9. Fayzrakhmanov RR. Anti-VEGF therapy of neovascular age-related macular degeneration: from randomized trials to real clinical practice. Russian Ophthalmological Journal. 2019;12(2):97–105 (In Russ). doi: 10.21516/2072-0076-2019-12-2-97-105.
10. Fayzrakhmanov RR, Voropaev VYu, Sukhanova AV, Shatalova EO. Antiangiogenic therapy of neovascular age-related macular degeneration. Vestnik oftal’mologii. 2021;137(1):83–93 (In Russ). doi: 10.17116/oftalma202113701183.
11. Brown DM, Tuomi L, Shapiro H; Pier Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab-treated eyes with neovascular age-related macular degeneration. Retina. 2013 Jan;33(1):23–34. doi: 10.1097/IAE.0b013e318263cedf.
12. Simader C, Ritter M, Bolz M, Deák GG, Mayr-Sponer U, Golbaz I, Kundi M, Schmidt-Erfurth UM. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration. Ophthalmology. 2014 Jun;121(6):1237–1245. doi: 10.1016/j.ophtha.2013.12.029.
13. Waldstein SM, Wright J, Warburton J, Margaron P, Simader C, Schmidt-Erfurth U. Predictive Value of Retinal Morphology for Visual Acuity Outcomes of Different Ranibizumab Treatment Regimens for Neovascular AMD. Ophthalmology. 2016 Jan;123(1):60–69. doi: 10.1016/j.ophtha.2015.09.013.
14. Bontzos G, Bagheri S, Ioanidi L, Kim I, Datseris I, Gragoudas E, Kabanarou S, Miller J, Tsilimbaris M, Vavvas DG. Nonresponders to Ranibizumab Anti-VEGF Treatment Are Actually Short-term Responders: A Prospective Spectral-Domain OCT Study. Ophthalmol Retina. 2020 Dec;4(12):1138–1145. doi: 10.1016/j.oret.2019.11.004.
15. Amoaku WM, Chakravarthy U, Gale R, Gavin M, Ghanchi F, Gibson J, Harding S, Johnston RL, Kelly SP, Lotery A, Mahmood S, Menon G, Sivaprasad S, Talks J, Tufail A, Yang Y. Defining response to anti-VEGF therapies in neovascular AMD. Eye (Lond). 2015 Oct;29(10):1397–1398. doi: 10.1038/eye.2015.159. Erratum for: Eye (Lond). 2015 Jun;29(6):721–731. Kelly S [corrected to Kelly SP].
16. Arnold JJ, Markey CM, Kurstjens NP, Guymer RH. The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration--a phase IV randomised clinical trial with ranibizumab: the FLUID study. BMC Ophthalmol. 2016;3:16–31. doi: 10.1186/s12886-016-0207-3.
17. Ashraf M, Souka A, Adelman RA. Age-related macular degeneration: using morphological predictors to modify current treatment protocols. Acta Ophthalmol. 2018;96(2):120–133.
18. Pastore MR, Milan S, Cirigliano G, Tognetto D. Functional and anatomical outcomes of brolucizumab for nAMD in a real-life setting. Sci Rep. 2024;14(1):1441.
19. Chandra S, Gurudas S, Pearce I, Mckibbin M, Kotagiri A, Menon G, Burton BJL, Talks J, Grabowska A, Ghanchi F, Gale R, Giani A, Chong V, Chen CNT, Nicholson L, Thottarath S, Chandak S, Sivaprasad S. Baseline characteristics of eyes with early residual fluid post loading phase of aflibercept therapy in neovascular AMD: PRECISE study report 3. Eye (Lond). 2024 May;38(7):1301-1307. doi: 10.1038/s41433-023-02886-1.
20. Zaitseva OV, Neroeva NV, Okhotsimskaya TD, Bobykin EV. Anti-VEGF Therapy of Neovascular Age-Related Macular Degeneration: Causes of Insufficient Efficacy. Vestnik oftal’mologii. 2021;137(5):152–159 (In Russ.). doi: 10.17116/oftalma2021137051152.
21. Spaide RF, Jaffe GJ, Sarraf D, Freund KB, Sadda SR, Staurenghi G, Waheed NK, Chakravarthy U, Rosenfeld PJ, Holz FG, Souied EH, Cohen SY, Querques G, Ohno-Matsui K, Boyer D, Gaudric A, Blodi B, Baumal CR, Li X, Coscas GJ, Brucker A, Singerman L, Luthert P, Schmitz-Valckenberg S, Schmidt-Erfurth U, Grossniklaus HE, Wilson DJ, Guymer R, Yannuzzi LA, Chew EY, Csaky K, Monés JM, Pauleikhoff D, Tadayoni R, Fujimoto J. Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group. Ophthalmology. 2020 May;127(5):616–636. doi: 10.1016/j.ophtha.2019.11.004.
22. Barış ME, Menteş J, Afrashi F. Subgroups and Features of Poor Responders to Anti-Vascular Endothelial Growth Factor Treatment in Eyes with Neovascular Age-Related Macular Degeneration. Turk J Ophthalmol. 2020;50(5):275–282. doi: 10.4274/tjo.galenos.2020.38488.
23. Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol. 2004;122:598–614. doi: 10.1001/archopht.122.4.598.
Review
For citations:
Likhvantseva V.G., Kapkova S.G., Tretyak E.B., Naumova V.I., Plieva H.M., Borisenko T.E. To Study the Role of Personalized Risk Factors for Poor Response to Angiostatic Therapy Based on Regression Models of the Disease. Ophthalmology in Russia. 2025;22(1):136-142. (In Russ.) https://doi.org/10.18008/1816-5095-2025-1-136-142